Ginkgo Bioworks Holdings - Asset Resilience Ratio
Ginkgo Bioworks Holdings (DNA) has an Asset Resilience Ratio of 22.81% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read DNA total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Ginkgo Bioworks Holdings's Asset Resilience Ratio has changed over time. See Ginkgo Bioworks Holdings book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Ginkgo Bioworks Holdings's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Ginkgo Bioworks Holdings (DNA) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $255.42 Million | 22.81% |
| Total Liquid Assets | $255.42 Million | 22.81% |
Asset Resilience Insights
- Good Liquidity Position: Ginkgo Bioworks Holdings maintains a healthy 22.81% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Ginkgo Bioworks Holdings Industry Peers by Asset Resilience Ratio
Compare Ginkgo Bioworks Holdings's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.10% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 30.29% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 4.52% |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180 |
Biotechnology | 4.28% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 83.49% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 41.74% |
Annual Asset Resilience Ratio for Ginkgo Bioworks Holdings (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Ginkgo Bioworks Holdings.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 22.81% | $255.42 Million | $1.12 Billion | -17.96pp |
| 2024-12-31 | 40.77% | $561.57 Million | $1.38 Billion | -15.88pp |
| 2023-12-31 | 56.65% | $943.42 Million | $1.67 Billion | +4.83pp |
| 2022-12-31 | 51.82% | $1.32 Billion | $2.54 Billion | -23.03pp |
| 2021-12-31 | 74.84% | $1.55 Billion | $2.07 Billion | +18.44pp |
| 2020-12-31 | 56.40% | $380.80 Million | $675.15 Million | -14.63pp |
| 2019-12-31 | 71.03% | $495.29 Million | $697.32 Million | -- |
About Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artific… Read more